SCHEMBL2364645

SCHEMBL2364645

CCn1cc(-c2ccncc2)c(-c2cccc(N(C(=O)CN(C)C)S(=O)(=O)c3cc(F)ccc3F)c2C)n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 3/20 0.35
BRAF P15056 3/20 0.33
MAPK1 P28482 2/20 0.33
MAPK3 P27361 1/20 0.33
CDC7 O00311 1/20 0.32
DBF4 Q9UBU7 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
PPARG P37231 1/20 0.32
PPARD Q03181 1/20 0.32
PPARA Q07869 1/20 0.32
HCRTR2 O43614 2/20 0.31
HCRTR1 O43613 1/20 0.31
AURKA O14965 2/20 0.31
AURKB Q96GD4 2/20 0.31
CSNK1D P48730 2/20 0.31
MAPK13 O15264 1/20 0.31
CSNK1E P49674 1/20 0.31
MAPK12 P53778 1/20 0.31
MAPK11 Q15759 1/20 0.31
MAPT P10636 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14718136 0.94 BRAF (0.33) MAPK14BRAFMAPK1MAPK3CDC7
SCHEMBL2313322 0.90 MAPK14 (0.35) MAPK14BRAFMAPK1MAPK3CDC7
SCHEMBL14108523 0.90 MAPK14 (0.35) MAPK14BRAFMAPK1MAPK3CDC7
SCHEMBL2358799 0.90 MAPK14 (0.39) MAPK14BRAFMAPK1MAPK3CDC7
SCHEMBL14719043 0.88 BRAF (0.33) MAPK14BRAFMAPK1MAPK3CSNK1D
SCHEMBL14719496 0.88 BRAF (0.35) MAPK14BRAFMAPK1MAPK3CDC7
SCHEMBL2359292 0.88 MAPK14 (0.35) MAPK14BRAFMAPK1MAPK3CDC7
SCHEMBL2316585 0.87 BRAF (0.35) MAPK14BRAFMAPK1MAPK3HCRTR2
SCHEMBL2364647 0.87 PPARG (0.36) MAPK14BRAFMAPK1MAPK3PPARG
SCHEMBL2358892 0.86 MAPK14 (0.35) MAPK14BRAFMAPK1MAPK3CDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2528909-B1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2016-06-22 EP claimed
EP-2528909-B1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2016-06-22 EP disclosed
US-8791265-B2 Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-07-29 US disclosed
US-20130053419-A1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) 2013-02-28 US disclosed
EP-2528909-A1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2012-12-05 EP disclosed
WO-2011092088-A1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053419-A1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K15, MAP3K19, CDK3 MAPK14 36/4885BRAF 21/4885MAPK1 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.